| Name | Title | Contact Details |
|---|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.
Mason Dental Lab is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Affymetrix, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Irvine Pharmaceutical Services, is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. To date, we have advanced five novel anti-CSC product candidates into more than a dozen clinical studies and we continue to pursue the discovery of additional novel anti-cancer stem cell therapeutics. All of our product candidates were discovered internally in our own research laboratories. OncoMed’s discovery efforts focus on cancer stem cells, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for cancer recurrence and metastases. Our product candidates target CSCs pathways by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. We believe our product candidates are distinct from current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer. We utilize our proprietary technologies to (1) identify, isolate and evaluate CSCs, (2) identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation, and (3) develop targeted antibody and other protein-based therapeutics that are designed to modulate cancer stem cell targets and inhibit the growth of CSCs. These targets are in pathways implicated in cancer biology and stem cell biology. Our current clinical and preclinical product candidates address targets in the Notch, Wnt and RSPO pathways, as well as other undisclosed fundamental CSC pathways.